<img height="1" width="1" style="display:none;" alt="" src="https://dc.ads.linkedin.com/collect/?pid=412980&amp;fmt=gif">



DoY-1.jpg

 

 

WINNERS

Anima_Biotech_Vertical_Logo-1
Lilly-1

US Deal of the Year

The Award - US

This award recognises companies that have executed a truly transformational and high value creating deal for both the company and the wider industry. The deal could be a licensing agreement, asset acquisition or a creative alliance or partnership.

Judges paid particular attention to:

  • Uniqueness or novelty of deal strategy/terms and structure.
  • Level of value creation/size of deal.
  • Strength of partner/partnership and deal teams.
  • Potential game/industry changing implications within next 12 months.
  • Post-deal performance

Company Description  

Anima Biotech is advancing Translation Control Therapeutics, the first and only platform for the discovery of small molecule drugs that specifically control protein production as a new strategy against hard and undruggable targets in many diseases.

Anima’s proprietary technology enables visualization and monitoring of target protein translation via pulses of light emitted by ribosomes. The fully automated high-throughput screening system discovers small molecules that modulate the light, as they decrease or increase the target protein’s production. The platform integrates proprietary technologies in biology, bioinformatics, image analysis, big data analysis and artificial intelligence algorithms in a cloud computing software architecture.

Anima is developing an internal pipeline across multiple therapeutic areas with high unmet need and hard targets. Current programs are in Fibrosis (inhibiting the synthesis of Collagen type I), Viral infections (Respiratory Syncytial Virus – interfering with viral protein synthesis), Oncology (C-Myc translation inhibitors) and Huntington's disease (monitoring mutant Huntingtin translation pausing).

Anima’s Translation Control Therapeutics platform is strategically designed for partnering with Pharma. The power of Anima’s approach was solidified with a $1B+ collaboration with Lilly for the discovery and development of translation inhibitors of several targets. Anima’s technology has been further validated by 5 granted patents, 14 peer reviewed publications and 17 scientific collaborations.

DOWNLOAD THE 2018 WINNERS